Clinical Trial Detail

NCT ID NCT02835222
Title Selinexor With Induction, Consolidation, and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Wake Forest University Health Sciences
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin + Selinexor

Age Groups: adult senior

No variant requirements are available.